logo.jpg
ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01
April 26, 2021 05:00 ET | ImCheck Therapeutics SAS
ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01 -- EVICTION is a multi-center trial evaluating Butyrophilin 3A-targeted activation of the anti-tumor immune...
logo.jpg
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01
November 11, 2020 07:00 ET | ImCheck Therapeutics SAS
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01 Preliminary EVICTION Phase I/IIa trial data shows...
logo.jpg
ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting
October 14, 2020 17:00 ET | ImCheck Therapeutics SAS
Marseille, France, October 14, 2020 – ImCheck Therapeutics today announced the acceptance of four clinical and preclinical data abstracts on its proprietary drug candidate ICT01 at the Society for...
logo.jpg
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01
September 10, 2020 05:46 ET | ImCheck Therapeutics SAS
ImCheck Achieves Initial Positive Independent Safety Reviewand Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01                        Company Receives FDA Approval for US IND ...